Precision CRISPR engineering, built for reproducible science.
GEMCRO maintains a cryobanked library of CRISPR/Cas9-engineered and NIFDS's disease models — immunodeficiency, oncology, neurodegeneration, metabolic and cardiovascular disease, and infection — produced on demand by IVF, with literature references available for many lines.
Built by the same team that runs the studies.
Model fidelity is hard to audit from a spec sheet. Here is what stands behind each line in this catalog.
In-house CRISPR/Cas9
Gene editing, breeding, and characterization happen end-to-end at GEMCRO's own Goyang R&D center — not outsourced to a third-party foundry.
From catalog to custom
Don't see what your study needs? GEMCRO's in vivo model experts take collaborative development requests directly — bring the biology problem, and a custom CRISPR line can be scoped from there.
Cryobanked for speed
Every line is held as frozen sperm or embryos and expanded to order via IVF, so production starts the day you confirm — not after a breeding queue.
Scaled for large cohorts
Published IVF protocols for cryopreserved C57BL/6 sperm let GEMCRO generate large, age-matched cohorts in a single production run — built for nonclinical studies that need real numbers, not a handful of animals.
From inquiry to a genotyped cohort.
Most lines are produced to order rather than held as a live breeding colony. Share your study timeline early so production can be scheduled against it.
Confirm model & timeline
Email contact@gemcro.com with the model, background strain, and your study start date.
IVF production
Cryopreserved sperm or embryos are thawed and used for in vitro fertilization to generate your cohort.
Genotyping & weaning
Offspring are PCR-genotyped and raised to a standard 4-week-old reference age.
Cohort ships
Typical total turnaround is 2–3 months from order confirmation to a weaned, genotyped cohort.
Already equipped for IVF or embryo transfer?
Many overseas labs and CROs run their own embryo manipulation. For these institutions, GEMCRO can ship cryopreserved sperm or embryos directly rather than producing a live cohort — skipping live-animal import permits and quarantine, and letting you run IVF on your own schedule.
Models organized by disease area.
To request any line below — or something not yet in the catalog — email contact@gemcro.com with the model name, background strain, and your study timeline.
Engraftment & humanized-immune-system backgrounds
Severely immunocompromised strains for xenograft, engraftment, and humanized-immune-system studies, including GEMCRO's proprietary N2G line.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
N2G NOD-Prkdcnull Il2rgnull immunodeficient model | KO | NOD | Whole-body | Kim et al., 2025 |
Prkdcnull SCID immunodeficient model | KO | Balb/c | Whole-body | Lee et al., 2018 |
Rag2null T/B cell-deficient model | KO | C57BL/6 | Whole-body | Lee et al., 2018 |
Rag2null T/B cell-deficient model | KO | FVB | Whole-body | Lee et al., 2018 |
Oncogene, tumor-suppressor & patient-mutation models
Constitutive and inducible lines for tumor biology, drug response, and resistance studies, including a published lung-cancer driver model.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
ApcL850X ApcMin mutation intestinal tumor model | KI | C57BL/6 | Endogenous | On request |
ApcI716X Apc truncation-based intestinal tumor model | KI | C57BL/6 | Endogenous | On request |
Tg(pCAG-LSL-EML4-ALK); Tg(SPC-CreERT2) inducible EML4-ALK lung cancer model | Tg | C57BL/6 | Lung-specific | Pyo et al., 2017 |
Trp53null p53-deficient tumor model | KO | C57BL/6 | Whole-body | Yun et al., 2021 |
Trp53null p53-deficient tumor model | KO | FVB | Whole-body | Yun et al., 2021 |
Trp53R172H Human p53 R175H-equivalent hotspot mutation | KI | C57BL/6 | Endogenous | On request |
Amyloid, tau & α-synuclein pathology
Brain-targeted neurodegeneration lines and a humanized risk-allele model supporting Alzheimer's, Parkinson's, tauopathy, and neuroinflammation studies.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
Tg(NSE-hAPPsw) Human APP, Swedish mutation | Tg | C57BL/6 | Brain | Son et al., 2018 |
Tg(NSE-hTau23) Human Tau | Tg | C57BL/6 | Brain | Data sheet |
Tg(NSE-hαSyn) Human α-synuclein | Tg | C57BL/6 | Brain | Lee et al., 2022 |
ApoeAPOE4 Humanized APOE4 model | KI | C57BL/6 | Endogenous | On request |
Obesity, diabetes, MASH & MAFLD
Leptin signaling, PNPLA3, and PPARγ-pathway lines supporting obesity, diabetes, insulin resistance, and fatty liver disease programs.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
Lepnull Leptin-deficient Ob model | KO | C57BL/6 | Whole-body | Kim et al., 2022 |
Leprnull LepR-deficient Db model | KO | C57BL/6 | Whole-body | Lee et al., 2025 |
Pnpla3I148M MAFLD risk model | KI | C57BL/6 | Endogenous | On request |
PpargS273A Insulin-sensitizing metabolic model | KI | C57BL/6 | Endogenous | On request |
Atherosclerosis, vascular inflammation, dyslipidemia & cardiac remodeling
Lipoprotein clearance, AGE–RAGE signaling, vascular inflammation, and immunoproteasome-related cardiovascular remodeling models.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
Apoenull Hyperlipidemia/atherosclerosis model | KO | C57BL/6 | Whole-body | On request |
Ldlrnull Diet-accelerated atherosclerosis model | KO | C57BL/6 | Whole-body | On request |
Agernull Vascular and metabolic inflammation model | KO | C57BL/6 | Whole-body | On request |
Tg(Ager); Tg(Tie2-CreERT2); Apoenull Endothelial-specific atherosclerosis model | Tg | C57BL/6 | Endothelial-specific | On request |
Psmb8/Psmb9 DKO Immunoproteasome-deficient model | KO | C57BL/6 | Whole-body | Lim et al., 2021 |
Adora2bD296G Cardioprotective variant model | KI | C57BL/6 | Endogenous | Lim et al., 2019 |
Humanized viral receptors & interferon-pathway models
Humanized receptor and interferon-pathway models supporting viral infection, host-response, and antiviral efficacy studies.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
Ace2em1(ACE2)Gmcr — hiACE2 Humanized ACE2 — viral infection model | KI | C57BL/6 | Endogenous | Park et al., 2024 |
Ifnarnull IFN-α receptor KO — viral infection model | KO | C57BL/6 | Whole-body | On request |
Ifngrnull IFN-γ receptor KO — host-defense infection model | KO | C57BL/6 | Whole-body | On request |
Human FcRn-mediated antibody recycling & translational PK
Humanized Fc receptor models supporting therapeutic antibody pharmacokinetics, FcRn-mediated recycling, and translational PK/PD studies.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
Fcgrtem1(FCGRT)Gmcr — hiFcRn Humanized FcRn — antibody PK model | KI | C57BL/6 | Endogenous | Lee et al., 2025 |
Complement pathway, phagocytosis & innate immune regulation
Complement-pathway and innate immune checkpoint models for immune-complex handling, inflammation, host defense, and phagocytosis studies.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
C1qanull Lupus-like autoimmunity model | KO | C57BL/6 | Whole-body | Kim et al., 2021 |
C3null Complement-deficient/host-defense model | KO | C57BL/6 | Whole-body | Choi et al., 2022 |
Cd47null "Don't-eat-me" signal-deficient model | KO | C57BL/6 | Whole-body | Kim et al., 2018 |
Il2ranull CD25 / Treg-related inflammation model | KO | C57BL/6 | Whole-body | On request |
Il2ranull CD25 / Treg-related inflammation model | KO | FVB | Whole-body | On request |
Progeroid aging, laminopathy & retinal degeneration
Progeroid aging and tissue degeneration models supporting aging biology, laminopathy, and retinal degeneration studies.
| Model | Type | Background | Expression | Reference |
|---|---|---|---|---|
LmnaG609G Progeroid laminopathy/accelerated-aging model | KI | C57BL/6 | Endogenous | On request |
Zmpste24flox Conditional progeroid aging model | cKO | C57BL/6 | Conditional | On request |
Pde6bR560C rd10 — retinal degeneration model | KI | C57BL/6 | Endogenous | Cha et al., 2022 |
Read the literature behind these models.
Catalog lines below are backed by published literature spanning immunology, oncology, neuroscience, cardiovascular biology, infectious disease, and antibody pharmacokinetics. Reference links for additional lines are in the catalog tables above.
Kim et al. — Characterization of the N2G (NOD-Prkdcnull Il2rgnull) immunodeficient mouse for engraftment and humanized-immune-system studies.
Pyo et al. — An EML4-ALK-driven inducible lung adenocarcinoma model for ALK-inhibitor pharmacology and resistance studies.
Lim et al. — Psmb8/Psmb9 double-knockout characterization of immunoproteasome function in vascular and metabolic phenotypes.
Park et al. — A humanized ACE2 mouse model recapitulating age- and sex-dependent immunopathogenesis of COVID-19.
Lee et al. — Advanced humanized FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies.
Lim et al. — Cardioprotective signaling through an Adora2b D296G variant in models of myocardial infarction.
Kim et al. — CRISPR/Cas9-mediated Cd47 knockout causes hemolytic anemia with splenomegaly, relevant to "don't-eat-me" checkpoint biology.
Yun et al. — Background-strain-dependent tumor sensitivity in Trp53-deficient FVB/N and C57BL/6 mice.
Don't see your model in the catalog?
Custom lines, in-development models, and lines under separate management can usually still be arranged — just email and we'll discuss it directly.